$VBLT is an Israeli biotech company.
The company's current focus is the development of a drug for ovarian cancer, which is currently in advanced stages (phase 3).
Additionally, they have a trial for brain cancer. Their drug is unique in the world. The market for such a drug is a market of billions.
So far, in both areas, the company is showing good results.
The company is considered a small cap company and is high risk. It recently received a price target of $5. This represents a one hundred percent upside from the market price.
This is not a short-term investment, but in my opinion, a long-term run could yield a very good return.
One last thing that I think is no less important: the management team all come from the fields of research and medicine.
Technical analysis: Current price: $2.06, first target (in my view): $3.05, second target (in my view): $5, stop loss: $1.87, debt to equity ratio: 0.2
The company has enough cash on hand until 2023 and for the completion of the trials.
This reduces the chance of an offering.
Personal opinion only! Anyone using this information does so at their own discretion and personal responsibility only.